An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
National News Bharat Tex 2026 Showcases India’s Global Textile Industry Ambitions India will host Bharat…
The central government set to strengthen the local self-government in Ladakh has received positive response…
As India's digital financial ecosystem continues to expand rapidly, cyber threats are becoming more sophisticated,…
As artificial intelligence (AI) is growing faster than before, but the ability to monitor and…
The procedure for the allocating of Tariff Rate Quota (TRQ) allocations has been formally announced…
For Gujarat agriculture sector, Geographical Indication (GI) tag awarded to Unjha cumin (Jeera) and Unjha…